Sarepta Therapeutics | SRPT - Operating Expenses



Sarepta Therapeutics reported $495.51M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Daiichi Sankyo JPY 377.89B 57.19B Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Insmed USD 361.29M 20.33M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Moderna USD 1.04B 113M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
PTC Therapeutics USD 213.73M 7.86M Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Sanofi EUR 9.02B 702M Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Tectonic Therapeutic USD 22.33M 8.34M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025